Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis

NCT07110844 is registered in ClinicalTrials.gov with Rajshekhar Chakraborty, MD as lead sponsor.

NCT NCT07110844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07110844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis
Lead sponsor
Rajshekhar Chakraborty, MD
Phase
Phase 2
Overall status
Recruiting
Start date
November 7, 2025
Completion date
October 31, 2033
Enrollment
25 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid light-chain amyloidosis